Zobrazeno 1 - 10
of 24
pro vyhledávání: '"M E, Bonneterre"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M.-E. Bonneterre, P. Guex
Publikováno v:
Oncologie. 8:906-909
De nombreuses questions psychologiques et ethiques surgissant au moment de decider du passage du curatif au palliatif en cancerologie; au-dela des aspects de toxicite medicamenteuse et des nombreuses consequences somatiques des traitements de dernier
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c896d23b2eadad7af39f38f1db8bbadf
https://doi.org/10.1007/s10269-006-0535-7
https://doi.org/10.1007/s10269-006-0535-7
Autor:
F. Mayer, Stéphane Culine, B. Bendahmane, Véronique Diéras, N. Dohoulou, M. Tubiana-Hulin, Thierry Delozier, Jacques Bonneterre, Philippe Bougnoux, M.-E. Bonneterre
Publikováno v:
British Journal of Cancer
The purpose of the study was to evaluate the efficacy and safety of docetaxel plus epirubicin (ET) and of 5-fluorouracil plus epirubicin and cyclophosphamide (FEC) as first-line chemotherapy for metastatic breast cancer. A total of 142 patients (inte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b58b7589c840de595eccb31b6052bb65
https://doi.org/10.1038/sj.bjc.6602179
https://doi.org/10.1038/sj.bjc.6602179
Autor:
Luc Thomas, Peter Mohr, B N Bui, R J Bensadoun, C de Gislain, Wolfgang Tilgen, Michèle Delaunay, Jens Ulrich, Didier Cupissol, M Clavel, S Bourdin, F Mornex, M Mousseau, Axel Hauschild, Thierry Lesimple, M E Bonneterre, Bernard Guillot
Publikováno v:
Melanoma research. 13(1)
The main objective of this prospective multicentre randomized phase III study was to compare a combined regimen of fotemustine plus whole brain irradiation with fotemustine alone in terms of cerebral response and time to cerebral progression in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e26e7b35c901395233dc13f61e17a056
https://pubmed.ncbi.nlm.nih.gov/12569292
https://pubmed.ncbi.nlm.nih.gov/12569292
Publikováno v:
Bulletin du cancer. 86(6)
In the context of a medicoeconomic study of the adjuvant treatment of breast cancer, we evaluated the cost of the recurrence. This cost was assessed from the medical records of 146 patients having presented either distant metastases, or a local recur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3fe41951b2ea3244e884a44250fb8e32
https://pubmed.ncbi.nlm.nih.gov/10417432
https://pubmed.ncbi.nlm.nih.gov/10417432
Publikováno v:
Bulletin du cancer. 85(11)
In this study a cost analysis of therapeutics used in the adjuvant treatment of breast cancer has been performed. Four strategies were considered: chemotherapy (FEC, 6 courses), hormone therapy (tamoxifen, 20 mg/day during 3 years), the association o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1b9a46a95601b3350647f5c4929bd32d
https://pubmed.ncbi.nlm.nih.gov/9951423
https://pubmed.ncbi.nlm.nih.gov/9951423
Autor:
P, Huc, S, Block, D, Carlier, F, Darloy, M E, Bonneterre, J P, Bleuse, C, Fournier, J, Bonneterre
Publikováno v:
Bulletin du cancer. 85(6)
It is a randomised cross-over multicenter study comparing the efficacy and the tolerance of granisetron (Gra) 1 mg and ondansetron (Ond) 8 mg, oral, given during two consecutive cycles to 188 naive patients scheduled to receive a moderately emetogeni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b084e69a7b60a9ba00b84ea7de0f9f95
https://pubmed.ncbi.nlm.nih.gov/9752283
https://pubmed.ncbi.nlm.nih.gov/9752283
Publikováno v:
Bulletin du cancer. 84(5)
In recent studies, the economic criteria has begun to be integrated to the appraisal in cancerology. The question asked by the economist can be framed as follows: what incremental cost should the collectivity or the health insurance system consent, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b3bc0814a8f5e0545543e996e7d617a9
https://pubmed.ncbi.nlm.nih.gov/9295860
https://pubmed.ncbi.nlm.nih.gov/9295860
Autor:
M. E. Bonneterre, M. Degardin, Eric Dansin, R. Beuscart, Antoine Adenis, Y Vendel, Stéphanie Clisant, Nicolas Penel, Jacques Bonneterre, Marie Vanseymortier
Publikováno v:
Journal of Clinical Oncology. 25:2568-2568
2568 Background: For investigators, the selection of patients to be considered for phase I clinical trials is difficult, because of the lack of objective criteria for a rational decision-making process. From October 1997 to October 2002, we retrospec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f43c7d9672885b91bebc866e53da306
https://doi.org/10.1200/jco.2007.25.18_suppl.2568
https://doi.org/10.1200/jco.2007.25.18_suppl.2568
Autor:
M. E. Bonneterre, J. Bonneterre
Publikováno v:
Annals of Oncology. 17:875
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c8be45cd0b5646298947bc5b4e760e1
https://doi.org/10.1093/annonc/mdj074
https://doi.org/10.1093/annonc/mdj074